Navigation Links
Biomerix Awarded Two Device Licenses by Health Canada
Date:4/19/2011

FREMONT, Calif., April 19, 2011 /PRNewswire/ -- Biomerix Corporation announced today it has received two Class III Medical Device Licenses by Health Canada for its REVIVE and ASSURE Hernia Repair Meshes.

REVIVE and ASSURE surgical meshes feature the Biomerix Biomaterial, a proprietary, biointegrative, synthetic tissue scaffold. The Biomerix Biomaterial is designed to play a role similar to the body's extracellular matrix, a biological structure that supports tissue repair and regeneration.  The three-dimensional, open-cell, and interconnected structure allows cells to migrate and proliferate to create new tissue. These meshes combine the strength of a synthetic material with the properties of a biologic, each offering its own set of distinctive benefits.

REVIVE is constructed with the Biomerix Biomaterial on both sides to maximize tissue ingrowth, a critical element in the repair of inguinal hernias. ASSURE is created for the repair of ventral hernias, with one side composed of the Biomerix Biomaterial to promote tissue ingrowth and the opposite side consisting of a resorbable protective film designed to minimize tissue attachment to the device in case of direct contact with the viscera.

"These regulatory approvals represent another step forward as Biomerix broadens its global reach with REVIVE and ASSURE. Both products will be distributed in Canada by Medline Industries pursuant to our exclusive distribution agreement," stated Kenneth G. Hayes, President and CEO of Biomerix Corporation.

About Biomerix

Biomerix Corporation develops and manufactures novel and proprietary materials to meet the needs of the medical, industrial, and consumer markets. Founded in 2001, Biomerix began developing a new class of polymeric material designed to support the tissue healing process. By 2004, the Company achieved a significant breakthrough and created the proprietary Biomerix Biomaterial™, a revolutionary biointegrative synthetic tissue scaffold. The Biomerix Biomaterial is a non-resorbable, cross linked, reticulated, polycarbonate polyurethane-urea consisting of an open-cell, three-dimensional, interconnected macroporous structure. This unique scaffold translates into an ability to support predictable, organized fibrovascular tissue ingrowth. The Biomerix Biomaterial is designed to play a role similar to the body's extracellular matrix (ECM), through the main phases of inflammation, proliferation, and remodeling.

For more information please call 888.308.3620 or visit www.biomerix.com.


'/>"/>
SOURCE Biomerix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomerix Granted CE Mark for its REVIVE™ Soft Tissue Repair Mesh
2. Biomerix Ventral Hernia Repair Mesh Receives FDA 510(k) Clearance
3. OmniComm Systems Awarded 4 Clinical Trials from U.S. Biotechnology Company
4. Winner Medical CEO Awarded and Appointed Position by CNITA
5. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
6. Bellicum Pharmaceuticals Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas
7. $2 Million Awarded to Duke University Prevention Epicenter to Study Reduction of Healthcare-Associated Infections Using Tru-D, Total Room Ultraviolet Disinfection
8. NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease
9. NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002
10. MV Sales and Leasing Awarded HGACBuy National Contract
11. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... The global immunomodulators market is expected ... to a new study by Grand View Research, ... driven by high R&D investments employed by the ... new and therapeutically advanced drugs. This is believed ... unprecedented rate into the immunomodulators market hence providing ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... Opportunities for Leading Companies – our new study reveals ... discusses issues and events affecting the Alzheimer,s disease therapeutics ... to answer these key questions: - How is the ...
(Date:1/19/2017)... 2017 According to a study conducted by ... to witness a CAGR of 6.5% during the forecast period 2016-2024. ... continue to be the leading market for cryotherapy globally during the ... Highlights ... ensuring affordable and adequate supply of gas in order to provide ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming ... set out for each of his children. “The Angel” is the creation of published ... in New York City, and impassioned writer. , When asked of her new book, ...
(Date:1/20/2017)... ... ... Forgive You”: a fine examination of how God handles sin, including how to let ... Stephen Miller, who, for over ten long years has been waiting to release this powerful ... Tobago, he has been serving the Lord for over twenty years, and he has been ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Christmas in ... creation of published author, Sara Seymour, who lives in Lafayette, Indiana where she works ... sips on iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Knowledge is ... be guided by faith. “Knowledge is God’s Lighthouse” is the creation of published author, ... cookbooks, novels, and poetry collections. , “I have been writing since high school ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All Odds”: ... creation of published author, Keith C. A. Tucker, son of Minister Delores Pinnock and ... pastured by Reverend Mark Hardy , “While sitting up in bed, I felt a ...
Breaking Medicine News(10 mins):